Oxford Nanopore Technologies plc (LON:ONT)
117.40
-4.40 (-3.61%)
Mar 9, 2026, 5:09 PM GMT
LON:ONT Revenue
In the year 2025, Oxford Nanopore Technologies had annual revenue of 223.90M GBP with 22.22% growth. Oxford Nanopore Technologies had revenue of 118.30M in the half year ending December 31, 2025, with 41.40% growth.
Revenue
223.90M
Revenue Growth
+22.22%
P/S Ratio
5.07
Revenue / Employee
167.72K
Employees
1,335
Market Cap
1.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 223.90M | 40.71M | 22.22% |
| Dec 31, 2024 | 183.19M | 13.52M | 7.97% |
| Dec 31, 2023 | 169.67M | -28.94M | -14.57% |
| Dec 31, 2022 | 198.60M | 64.94M | 48.59% |
| Dec 31, 2021 | 133.66M | 19.80M | 17.39% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.00M |
| Oxford Biomedica | 151.21M |
| PureTech Health | 4.66M |
| Avacta Group | 113.00K |
| Scancell Holdings | 4.71M |
| 4basebio | 1.78M |
| Bioventix | 13.12M |
| Faron Pharmaceuticals Oy | 1.14M |
Oxford Nanopore Technologies News
- 7 days ago - Full Year 2025 Oxford Nanopore Technologies PLC Earnings Presentation Transcript - GuruFocus
- 10 days ago - Oxford Nanopore Technologies PLC (LSE:ONT) Q4 2025 Earnings Report Preview: What To Look For - GuruFocus
- 2 months ago - Oxford Nanopore Receives Regulatory Approval for its First Diagnostic Device in the UK and Europe - Business Wire
- 5 months ago - Oxford Nanopore Announces PromethION Plus Flow Cell and Human Genetics Updates at ASHG 2025 - Business Wire
- 7 months ago - ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology - Business Wire
- 11 months ago - Breakthrough algorithm enables partially phased, near telomere-to-telomere assembly using standard Oxford Nanopore Simplex reads - Business Wire
- 11 months ago - Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem - Business Wire
- 1 year ago - Oxford Nanopore and UK Biobank to create world's first epigenetic dataset targeting the causes of cancer, dementia, complex disease - Business Wire